
Drugs IPOs Depend o...


| BIRT | Sector Avg. | S&P 500 |
|---|---|---|
| 35.42 | 35.40 | 17.70 |
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 6.58 | 0.91 | 0.00 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 2.90 | 0.16 | 0.05 |
| Net Income | 0.00 | 0.00 | |
| EPS | -13.00 | -0.22 | -0.08 |
| EBITDA | 23.80M |
| REVENUE | 138.82M |
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.06 | $0.06 | $0.26 | $0.32 |
| Number of Analysts | 4 | 4 | 4 | 4 |
| High Estimate | $0.07 | $0.08 | $0.29 | $0.37 |
| Low Estimate | $0.05 | $0.05 | $0.25 | $0.28 |
| Prior Year | $0.08 | $0.04 | $0.25 | $0.26 |
| Growth Rate (Year over Year) | -25.00% | 56.25% | 5.00% | 20.95% |